Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that trading in the Company’s Ordinary Shares of nominal value of £0.02 each will commence today on the OTCQB Venture Market in the United States. The Company’s OTCQB shares will have the ticker: POLBF.
There is no associated capital raise with this cross trading and Poolbeg’s Ordinary Shares will continue to trade on the Alternative Investments Market (AIM) on the London Stock Exchange under ticker POLB. Cross trading on the OTCQB market allows the Company access to one of the world’s largest investment markets to expand its reach into a broader pool of investors. Poolbeg shares will be available to US investors during US working hours and priced in US dollars and thus has the potential to enable greater liquidity in Poolbeg shares on AIM by easing cross-border trading for potential US investors.
As a Foreign Private Issuer, Poolbeg’s onboarding to the OTC Markets is based on satisfaction of the requirements for OTCQB as applicable to international reporting companies including satisfaction of the criteria for the exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the company’s website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs, compared to traditional major exchanges.
As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world’s largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments for Poolbeg at www.otcmarkets.com.
Since the Company listed on AIM in July 2021, it has continued to make significant progress on its strategy to develop multiple innovative infectious disease products faster and more cost effectively than the conventional biotech model. Key strategic areas have included:
| Driving the clinical development of its POLB 001 programme for severe influenza which is expected to report initial data from its forthcoming human challenge trial before the end of 2022 |
| Delivering on its plans to leverage its proprietary databank of human challenge study derived disease progression data to identify new pharmaceutical assets using artificial intelligence, most recently signing a deal with CytoReason to interrogate its influenza data |
| Obtaining licensed access to use micro- and nanoencapsulation technology to develop oral vaccines for multiple disease indications |
| Adding a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002) to its portfolio |
| Signing an option to licence a vaccine against the tropical and subtropical disease Melioidosis (POLB 003), while also evaluating a further 5 bacterial vaccine candidates |
Poolbeg engaged Nikolaos Galanopoulos of the corporate securities law firm Galanopoulos & Company as its OTC Markets Sponsor for the OTCQB onboarding.
Cathal Friel, Chairman of Poolbeg Pharma said:
“We believe that having a US cross trading facility is important for the development of Poolbeg. It gives us the opportunity to widen our potential investor base, which we believe may help future liquidity, and capitalises on the interest in European stocks from US investor. In our view, OTCQB is a good complement to our AIM listing. The OTC markets have expanded in recent years beyond pink sheet listings, and now include a premium market (OTCQX) for companies such as Danone and Roche, and a venture market (OTCQB) for companies of Poolbeg’s size.”
Jeremy Skillington, CEO of Poolbeg Pharma added:
“Importantly, the OTCQB trading facility will provide access to one of the world’s largest investments markets with no additional reporting obligations and minimal ongoing costs, compared to traditional major exchanges. This cross trading facility has the potential to enable greater liquidity in Poolbeg shares on AIM by easing cross-border trading for potential US investors.
We believe this listing will enable US institutional and retail investors to share in the growth of Poolbeg as we build the Company into a leading infectious disease pharmaceutical company. This action also fits with our long-term strategy and ambitions to be dual listed on a national securities exchange in the US, such as Nasdaq, subject to meeting their listing requirements; this is a step in the right direction.”
Jonathan Dickson, VP of International Corporate Services at OTC Markets, said:
“We are delighted to welcome Poolbeg Pharma to the OTCQB Venture Market. With its primary listing remaining on London’s AIM, the OTCQB’s cross-trading facility will allow Poolbeg to broaden its horizons and provide investors in the U.S. with the ability to access the Company’s Ordinary Shares in U.S. dollars and during U.S. market hours.”
